CADDA Knowledge Transfer Vouchers Funding Awarded
EMQN is pleased to announce that it has been awarded funding through the CADDA Knowledge Transfer Vouchers scheme for the project “Engineered CYP2C19 Cell Lines for Point‑of‑Care Test (POCT) Quality Assessment”, delivered in collaboration with The University of Manchester.This project will apply CRISPR‑Cas9 genome editing to develop high‑quality, well‑characterised reference materials containing clinically important variants […]
EMQN Named Finalist in the 2026 UK & Ireland Inspiring Workplaces Awards
EMQN CIC is proud to announce that it has been named a finalist in the 2026 UK & Ireland Inspiring Workplaces Awards, in association with Prezzee, placing the organisation among a prestigious group of employers recognised for putting people at the heart of their culture. The Inspiring Workplaces Awards are recognised globally as the world’s […]
EMQN and Ridacom Join Forces to Elevate Genomics Quality in Southeast Europe
We’re thrilled to announce a strategic partnership between EMQN CIC and Ridacom Ltd, a leading provider of laboratory solutions across Bulgaria, Greece, and Albania. This exciting collaboration marks a major milestone in our mission to make high-quality genomics accessible across Southeast Europe. Through this partnership, Ridacom will become EMQN’s trusted regional distributor, helping clinical laboratories […]
Microbix Assisting EMQN with Second Genetic-Test EQA Program
Helping Ensure Appropriate Dosing of Widely-Used Anti-Clotting Drugs MISSISSAUGA, CANADA & MANCHESTER, UK – September 23, 2025 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and EMQN CIC (EMQN), a global supplier of laboratory external quality assessment (“EQA”) schemes for human genomic testing, announce the go-live of […]
EMQN CIC is pleased to announce the launch of a new EQA scheme for CYP2C19 Point-of-Care Testing (POCT), suitable for use with the NICE-recommended Genedrive® CYP2C19 ID Kit.
CYP2C19 Point-of-Care Pharmacogenomic EQA Scheme EMQN CIC’s CYP2C19 EQA scheme is designed to support the accurate and timely identification of CYP2C19 variants in acute clinical settings. This ensures that patients—particularly those presenting with recent ischaemic stroke or transient ischaemic attack (TIA)—receive the most appropriate antiplatelet therapy. Identifying CYP2C19 poor or intermediate metabolisers enables tailored clopidogrel prescribing, which may improve clinical […]
The 2026 EQA catalogue is now available
We are proud to present to you the new EQA schemes for 2026, allowing more flexibility, time and cost efficiency, ease of purchase, and more. Our goal is to ensure the highest genomic diagnostic quality from lab to patient, and our updated schemes will help you get there, tailoring our services to your needs. Check our […]